ABSTRACT The oligosaccharide fraction of human milk, the third most abundant solid constituent, consists of hundreds of structures, many of them fucosylated. Oligosaccharides may bear structural homology to cell surface glycoconjugates used as receptors by pathogens, thus protecting nursing infants. The ability of human milk to protect against heat-stable enterotoxin of Escherichia coli in suckling mice has been attributed to neutral fucosylated oligosaccharides of milk. The same phenomenon has been found in human T84 cells, allowing the mechanism of inhibition by the oligosaccharide to be studied in vitro. The oligosaccharide binds to the extracellular domain of guanylyl cyclase, thereby inhibiting the binding of stable toxin. The protective oligosaccharide is a large structure present in too low a concentration to be routinely measured directly; however, its concentration in milk may be inferred by measuring smaller, more plentiful, structurally homologous oligosaccharides. The adhesion by invasive pathogenic strains of Campylobacter to their enterocyte target is also inhibited by human milk fucosyloligosaccharides. Because Campylobacter binds H-2 type oligosaccharide structures, the concentration of protective oligosaccharide may also be inferred from the total oligosaccharide profile. The relationship between oligosaccharide profile heterogeneity in human milk and the incidence of specific gastrointestinal bacterial disease in infants consuming these milks could indicate the significance of these oligosaccharides to infant health. The efficacy of synthetic analogs of active oligosaccharides will confirm their clinical relevance and define minimum structural features essential for activity. J. Nutr. 127: 980S-984S, 1997.
charides were long believed not to have biological significance.
HUMAN MILK OLIGOSACCHARIDES
Their presence was attributed to the accident of a high concentration of lactose occurring in the presence of large amounts The human milk oligosaccharide fraction was described in and numbers of glycosyltransferases, the enzymes responsible 1933 (Polonovsky and Lespagnol 1933) . The several laborafor the synthesis of complex carbohydrate moieties of glycoprotories reporting quantitative data on this fraction are in general teins and glycolipids (Kobata 1978) . agreement that it represents over 12 g/L of mature milk and Close to 90 major milk oligosaccharides have been isolated approximately 22 g/L of colostrum. This consensus is the more and their structures determined. The oligosaccharides generconvincing because of the very disparate methods of analysis ally have a lactose moiety at the reducing end of the molecule that were used for its quantification (Newburg and Neubauer and often contain a fucose and/or sialic acid moiety at the 1995). Thus, the oligosaccharide fraction of human milk is the nonreducing end. The number of potential structural permutathird largest solid component, after fat and lactose. However, tions for the oligosaccharides is astronomical. Using state-ofdespite having a higher concentration in human milk than the-art time-of-flight mass spectrometry, Stahl et al. (1994) protein, a fraction of widely recognized importance, oligosacdetected approximately 900 fucosyloligosaccharides containing up to 32 sugars and up to 15 fucose residues. With 1 Presented as part of the symposium entitled ''Bioactive Components in Milk such a large array of structures, it becomes increasingly plausi- and other humoral effectors; however, an essential first step for
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Because the milk oligosaccharides seem to be synthesized by an extracellular region that includes the binding site for ST, an intracellular domain that includes a region with protein glycosyltransferases similar to those that synthesize glycoprotein and glycolipid cell surface components (Kobata 1978) , it kinase activity, and a region with guanylyl cyclase activity. Stable toxin binds to the extracellular region, which causes is reasonable to postulate that some of these oligosaccharides could have structural homology to cell surface carbohydrates.
the activation of guanylyl cyclase in the intracellular domain, leading to elevated production of cGMP from GTP. The eleThese could act as analogs or homologs of host cell surface receptors for pathogens, thereby inhibiting the ability of the vated cGMP causes an inhibition of chloride channel function, resulting in a net flux of fluid to the lumen of the intestine pathogen to bind to the homologous cell surface glycoconjugate. Infants, whose stomachs are less acidified than those of across the microvillus membrane. This is thought to account for the mechanism of secretory diarrhea caused by stable toxin adults and whose immune systems are not mature, may need additional protection from enteric pathogens; oligosacchaof E. coli. The ability of the human milk oligosaccharide to inhibit rides, a major milk fraction composed of water-soluble cell surface analogs that can inhibit enteropathogen binding to this process was tested on membrane preparations of T84 cells; none of the oligosaccharide fractions alone changed basal guahost cell receptors, could serve such a protective function.
This concept is supported by several examples. Andersson nylyl cyclase activity. Stable toxin alone caused a significant elevation of guanylyl cyclase activity, consistent with its et al. (1986) reported that specific oligosaccharides obtained from human milk can inhibit binding of Streptococcus pneumonknown mechanism of action. The total oligosaccharide fraction and the ulex-binding fucosylated oligosaccharide fraction iae to its receptor. Similarly, Cravioto and co-workers (1991) described a milk oligosaccharide that inhibits adherence of inhibited ST-stimulated guanylyl cyclase activity by 70-80% in a dose-dependent manner, whereas the non-ulex binding, enteropathogenic E. coli to their receptors. We found that a fucosylated oligosaccharide inhibits the toxicity of stable toxin mainly nonfucosylated, oligosaccharide fraction did not inhibit. These data indicate that the oligosaccharide most likely of E. coli in vivo ) and that another fucosylated oligosaccharide inhibits binding of invasive strains acts by preventing toxin-mediated activation of guanylyl cyclase (Crane et al. 1994 ). of Campylobacter jejuni to its host cell (Ruiz-Palacios et al. 1992) . Details of these latter two examples follow.
Because the oligosaccharide and the toxin both seem to act extracellularly, the most likely mechanism of protection by the oligosaccharide would be the inhibition of ST binding to A FUCOSYLOLIGOSACCHARIDE ACCOUNTS the extracellular docking domain of guanylyl cyclase. There-
FOR THE PROTECTION AGAINST HEAT-STABLE
fore, the ability of the milk oligosaccharides to inhibit the ENTEROTOXIN BY HUMAN MILK binding of ST to T84 cell membranes was measured. The total oligosaccharide fraction inhibited 125 I-labeled ST binding by Enterotoxigenic E. coli are pathogens that cause gastroen-17%, and the fucosylated oligosaccharide fraction at half the teritis in adult travelers to many areas of the globe and in concentration inhibited ST binding by 27%. infants indigenous to these regions. Two major enterotoxins
The ability of the oligosaccharide to inhibit ST activation can be responsible for the secretory diarrhea that follows infecof guanylyl cyclase persisted even after oligosaccharide-treated tion: heat-stable enterotoxin (ST) and heat-labile enterotoxin. cells or cell membranes were washed to remove free oligosacHeat-labile enterotoxin resembles cholera toxin and the toxin charides prior to adding ST; this inhibition was equivalent to of C. jejuni in that it binds to the monosialyl ganglioside 1 that seen in controls in which oligosaccharides and ST were (GM1) on the cell surface as an essential step in its pathogenepresent together. These results led to the conclusion that the sis, and the GM1 of human milk inhibits its diarrheagenic active component of the milk oligosaccharide fraction binds effect (Otnaess et al. 1983) .
to the ST receptor rather than to the toxin. In 1983, Cleary et al. reported that human milk contained These data suggest the following mechanism whereby the a low-molecular-weight, nonprotein inhibitor of the action of human fucosylated oligosaccharide inhibits ST activity in ST. In subsequent work, a human milk oligosaccharide fraction mammalian intestines. The active human milk fucosyloligowas isolated that, at the concentrations found in milk, inhibits saccharide inhibits the action of ST by docking with a carbohy-ST in vivo in the suckling mouse model. The protective oligodrate recognition domain in the extracellular region of guanysaccharide is neutral and binds to lectin 1 of ulex europaeus, lyl cyclase. This active oligosaccharide may bind allosterically indicating a fucosylated oligosaccharide. These conclusions are to the extracellular portion of guanylyl cyclase proximal to the supported by the successful isolation of this activity by different ST binding site rather than competing directly for the ST isolation schemes and by the strong and unambiguous inhibibinding site itself. This bound oligosaccharide would interfere tion of ST activity in two different in vivo test systems (Newwith the ability of extracellular ST to cause an elevation of burg et al. 1990) . intracellular guanylyl cyclase activity in enterocytes. Without However, in the studies with suckling mice, the mechanism the elevation of cGMP, chloride channels are able to function of protection of the oligosaccharide could not be determined, normally, allowing the resorption of fluid from the intestinal and the protective efficacy of the oligosaccharide in human lumen and thereby preventing the secretory problem normally intestinal tissue was untested. The relevance of the inhibitor induced by exposure to ST. This may account for the observed to human cells and its mechanism of inhibition were investiinhibition of ST-induced secretory diarrhea in vivo by human gated in T84 cells, an in vitro model for ST action on intestinal milk oligosaccharides and represents a novel protective mechaepithelium. These cells express many of the features of human nism for human milk oligosaccharides. intestinal epithelium, including tight junctions, desmosomes and microvilli on the apical surface. These cells also express ISOLATION OF THE ACTIVE guanylyl cyclase. FUCOSYLOLIGOSACCHARIDE The first step towards studying the details of these phenom-
MECHANISM OF INHIBITION
ena is to isolate and identify the protective oligosaccharide so that its essential structural features can be defined and related Guanylyl cyclase is a transmembrane protein found on the microvillus membrane. It contains a transmembrane domain, to function.
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SUPPLEMENT
The ulex europaeus-bound fucosylated oligosaccharide fracfluence their breast-fed infants' susceptibilities to specific enteric diseases. tion was resolved by semipreparative HPLC into more than 30 distinct fractions. Only one of these displayed reproducible,
To test whether the ST inhibitory oligosaccharide in milk protects infants from gastrointestinal bacteria, the heterogenerobust, inhibitory activity. Therefore, this fraction was resolved by reversed-phase HPLC chromatography into seven distinct ity of milk oligosaccharide profiles will be tested for any relationship to the history of ST-associated enteric disease in the peaks, each of which was purified to homogeneity. When tested at 2.5 times their original concentrations in milk, only infants consuming this milk. Synthetic oligosaccharide analogs will be evaluated for their ability to inhibit ST of E. coli in one of these showed inhibition, and this was comparable to that of the control human milk sample. Testing was at this vivo, to identify simplified structures suitable for large-scale synthesis. This synthetic material will be utilized in detailed higher level to take into account probable losses in the many steps of its purification from pooled human milk. This single studies on the mechanism by which fucosyloligosaccharides inhibit ST docking to guanylyl cyclase and to test whether an fucosylated oligosaccharide peak is present in human milk at approximately 40 parts per billion (approximately 20 pmol/L) ST-binding inhibitor is efficacious in humans. and may be responsible for the protective activity of human milk against ST-induced enteric fluid loss in infant mice. CAMPYLOBACTER
In many of the developing regions of the world, Campylo-GENETIC HETEROGENEITY OF
bacter jejuni is responsible for much of the bacterial diarrhea MILK OLIGOSACCHARIDES that threatens infants. The pathogenesis of Campylobacter diarrhea involves a series of complex events, including toxin proThe isolation of this active oligosaccharide peak provided valuable clues to its structure. Adsorption to ulex europaeus duction and adherence to gut mucosa followed by its invasion. Thus, the inhibition of attachment to mucosal surfaces would affinity columns was a definitive step in the separation of the active fraction from other oligosaccharides, indicating that the disrupt an essential early step in the pathogenesis of Campylobacter infection. The binding of invasive (pathogenic) strains active oligosaccharides must contain fucosyl 1-2 linkages, the major binding determinants for this lectin. It seems to be a of Campylobacter to their target epithelial cells is inhibited in vitro by human milk, and specifically by the isolated fucosylarge structure of more than 10 sugar residues.
Fucosyl 1-2 linkages are synthesized in the mammary gland lated oligosaccharides of human milk. Infection by Campylobacter in a BALB/c mouse intestinal colonization model is also by fucosyl a1-2 transferases. Fucosyltransferases in milk probably reflect fucosyltransferases active in the Golgi apparatus of inhibited by these oligosaccharides. Five days after inoculation, mouse gut colonization by Campylobacter was 1.1 1 10 9 colonythe acinar cells of the breast epithelium. Milk fucosyltransferase activity varies among individuals; furthermore, the activity forming units per gram of feces in controls, whereas feces of similar mice fed oligosaccharide contained only 1.2 1 10 5 changes over the course of lactation. Such differences in transferase activities could reflect qualitative as well as quantitative colony-forming units per gram. The full structure of the milk oligosaccharide that inhibits differences in fucose-containing oligosaccharides of milk from different individuals and from different stages of lactation Campylobacter has not been determined. However, a bacterial binding immunoblot assay using a panel of defined albumin-(Wiederschain and Newburg 1995). For example, human milk oligosaccharide profiles are characteristic of the individual's linked carbohydrate chains was developed; Campylobacter bound to immobilized oligosaccharides with the H-2 type Lewis blood group type and secretor status, which reflect genetic differences in fucosyltransferases (Viverge et al. 1990 ).
structure (Fuca1-2Galb1-4GlcNAc), and less to those of the H-1 type (Fuca1-2Galb1-3GlcNAc) and the Lewis b type [Fuca1-2Galb1-3(Fuca1-4)GlcNAc] (Cervantes et al. 1995) .
OLIGOSACCHARIDE MEASUREMENT
Structures with these moieties are found in the human milk IN HUMAN MILK oligosaccharides. These data suggest that the human milk inhibitor of CampyThe complex structure and low concentration of the proteclobacter binding could be a1-2 fucosylated oligosaccharides tive oligosaccharide fraction in milk, which contains large that compete with the receptors present in epithelial cells; the amounts of related fucosyloligosaccharides, make it unlikely human milk fucosylated oligosaccharides inhibit the bacterium that levels of the protective oligosaccharide can be measured in vitro and in vivo. Again, the relevance of these findings to directly by a simple routine assay. However, structural features the protection of infants from Campylobacter infection by huthat some oligosaccharides have in common, such as fucosyl man milk can be tested by relating oligosaccharide profiles in a1-2 linkages, are thought to be synthesized by the same or milk samples to the incidence of Campylobacter diarrhea in closely related fucosyltransferases. Therefore, the relative infants consuming those milk samples. The efficacy of synamount of the protective oligosaccharide in the milk of an thetic analogs of a1-2 fucosyloligosaccharides in preventing individual may be related to the amount of structurally related Campylobacter infection in humans will also address this issue. smaller, more plentiful fucosyloligosaccharides. We developed a sensitive method for routine identification and quantification of milk oligosaccharides and tested the method by measuring PROTECTION OF THE HUMAN INFANT individual differences of oligosaccharide profiles in 50 random human milk samples (Newburg et al. 1996) . The profiles conMany studies have demonstrated that breast-feeding protects against enteric disease (Feachem and Koblinsky 1984) . sisted of more than 12 oligosaccharide peaks composed of trito octasaccharides. Variations in oligosaccharide profiles of In one example from Lehore, Pakistan, Hanson et al. (1991) analyzed breast-feeding protection of neonates by the same individual samples were related significantly to variations in fucosyltransferase levels. This implies that lactating mothers type of statistical treatment as one would use for an antibiotic drug, i.e., efficacy in preventing enteric disease in a population may differ genetically in their ability to produce protective oligosaccharides. If the protective oligosaccharide makes a sigat risk. Breast-feeding was most efficacious among rural and urban poor and during early lactation; however, it also pronificant contribution toward protecting the infant from disease, such genetic variation among lactating women may intected upper middle-class infants, whose level of hygiene and Newburg (1996) .
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economic status are more relevant to typical Western populaoligosaccharides may bind to the cell surface receptor and thereby inhibit the ability of the pathogen to affect the host tions.
Protection of neonates by breast-feeding may be attributed cell.
The quantity and types of oligosaccharides in milk seem to to many factors, including decreased exposure to pathogens, some aspects of breast-feeding per se, and the human milk be characteristic to each species. Therefore, common artificial diets for infants would not be expected to contain oligosacchacomponents. Protection from environmental pathogens by human milk components may include several tiers of defense, rides that are qualitatively or functionally comparable to those of human milk, because they would be unlikely to resemble perhaps compensating for the lack of a highly acidic stomach to act as a barrier to enteric pathogens and for the immaturity human cell surface receptors. The milks of other species may contain oligosaccharides that protect infants of that species of the immune system. First, human milk provides a complement of nutrients that optimize development of the intestinal against species-specific pathogens. Many aspects of the inhibitory oligosaccharides in relation mucosa and immune system. In addition, many major milk components, which may be sources of nutrients, may also be to protection of infants require further study: heterogeneity of milk glycoconjugates as a function of maternal genetics, stage capable of protecting against disease. This second tier of defense includes multifunctional and broad spectrum inhibitory of lactation, nutritional status, disease, and exposure to environmental agents should be investigated. The persistence and activities, such as lactoferrin, free fatty acids and monoglycerides. Many of these materials can protect against a wide range modification of milk oligosaccharides during transit through the infant's gastrointestinal tract may be highly relevant to of pathogens. Most widely recognized of the milk protective components is a third tier of defense, the antibodies, particutheir clinical significance. Details on the mechanisms by which these milk components inhibit pathogenesis require more inlarly the secretory immunoglobulin A that is so important to mucosal immunity. Wider interest is now emerging on a possivestigation, including structure-function relationships. To directly address the issue of whether the binding properties of ble fourth tier of protection, i.e., cell surface homologs that can inhibit pathogen binding to their host cell receptors. oligosaccharides in milk protect infants from gastrointestinal bacteria, a measure of the levels of the protective oligosacchaThese are, for the most part, nonnutrient glycoconjugates such as glycolipids, glycoproteins, mucins, glycosaminoglycans and rides in individual milk samples, such as the oligosaccharides profiles discussed above, must be related to the incidence of the oligosaccharides. Although the relative contributions of these different defense mechanisms, either individually or in diarrhea associated with specific pathogens in a nursing population at risk for this disease. The efficacy of synthetic neoglycoconcert, are unknown, recognition of the potential for the milk oligosaccharides to contribute significantly to the defense conjugates containing essential structural features of the milk oligosaccharides would strongly support the clinical relevance of the infant is increasing. Other bioactive constituents of milk may also contribute toward protection. These several tiers of the human milk oligosaccharides. of defense have the potential to work synergistically. Upon exposure of the nursing dyad to a pathogen, constitutive pro-LITERATURE CITED tective factors may control pathogens early in the infection,
